Gilead ups its bet on HIV, hep B, inking $400M partnership with immunotherapy company Hookipa
In search of new assets to bolster its leading HIV franchise, Gilead is enlisting the help of immunotherapy specialists at Hookipa Biotech to bring in some fresh R&D.
Topped with $10 million upfront and worth up to $400 million, the deal gives Gilead exclusive access to Hookipa’s arenavirus vector-based immunization technologies, Vaxwave and TheraT. As well as HIV, the Foster City, CA-based big biotech will also take a crack at hepatitis B using these viral platforms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.